Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
22OCT

CuspAI raising $400m on Bezos money

4 min read
16:30UTC

CuspAI, a 2024 Cambridge AI-materials company, has signed term sheets for a reported $400m round at a $2.6bn valuation with Bezos Expeditions among the backers. The round is not yet closed.

TechnologyDeveloping
Key takeaway

The fortnight's biggest UK round is foreign-led and not yet closed.

CuspAI, a Cambridge AI-materials company founded in 2024, is raising a reported $400m at a $2.6bn valuation, with Bezos Expeditions and Kleiner Perkins among the backers, according to the Financial Times⁠1. Term sheets are signed; the round is still being raised and has not closed⁠2. If it completes, the valuation lands at more than four times the company's September 2025 mark. Geoffrey Hinton and Yann LeCun, two of the people who built modern deep learning, sit on its advisory board.

The company solves a narrow problem. A customer specifies the properties it needs, a heat-resistant coating, a catalyst, a filter, and the platform generates candidate molecular structures and simulates them in silico before anyone touches a lab bench, compressing a discovery cycle that historically ran for years of wet-lab iteration. Meta is a customer for carbon-capture materials, Hyundai is another, and CuspAI worked with the Finnish chemicals group Kemira on materials to strip PFAS (per- and polyfluoroalkyl substances, the so-called forever chemicals) from water⁠3.

PhysicsX took its $300m Series C from Singapore's Temasek, and Orbital Industries closed an earlier Series B with no UK lead investor at all, the same shape the CuspAI round now repeats. British seed money is being rebuilt at the bottom of the market while the largest rounds are underwritten from Seattle and Singapore, which in practice means the founders stay in Cambridge while the upside accrues to investors abroad. AI-materials is the newest vertical to mint a near-unicorn this way, and it did so without a domestic lead.

Deep Analysis

In plain English

When a scientist or engineer needs a new material with specific properties ; say, a coating that resists extreme heat, or a filter that removes toxic chemicals from water ; the traditional approach is to mix and test compounds in a laboratory over months or years. CuspAI, a Cambridge startup founded in 2024, uses AI to do that work computationally: the computer generates and tests thousands of candidate molecules before anyone touches a lab bench. On or around 20 June 2026, the Financial Times reported that CuspAI is raising $400m from investors including Jeff Bezos's personal investment fund and the Silicon Valley firm Kleiner Perkins, at a reported valuation of $2.6bn. Term sheets have been signed, but the deal has not yet formally closed, so these figures are not confirmed. If the round does close at that valuation, it would make CuspAI worth more than four times what investors valued it at in September 2025. PFAS ; per- and polyfluoroalkyl substances, sometimes called 'forever chemicals' ; are a class of industrial compounds that persist in the environment and have been linked to health problems. CuspAI is working with the Finnish chemicals company Kemira to find materials that can remove PFAS from water, which is one reason industrial customers are interested even at this early stage.

Deep Analysis
Root Causes

AI-materials discovery requires a specific combination of frontier compute (for running molecular simulations at scale), large curated materials datasets, and the ability to hire researchers at the intersection of computational chemistry and machine learning.

UK universities produce the researchers; the compute and dataset infrastructure is concentrated in the US. Kleiner Perkins and Bezos Expeditions have direct relationships with the hyperscaler infrastructure that makes the product work, making them strategically useful LPs beyond the capital itself.

The valuation step-up mechanism ; more than four times the September 2025 mark ; reflects a commercial pull from industrial customers that was not visible at the earlier round. Meta's carbon-capture materials work, Hyundai's materials R&D, and Kemira's PFAS-removal brief are enterprise contracts large enough to reset the growth-capital case, and US growth investors are faster at repricing when enterprise traction signals product-market fit.

What could happen next?
  • Consequence

    A successful CuspAI close at $2.6bn resets UK AI-materials valuation benchmarks and is likely to attract further foreign capital into Cambridge's materials-science cluster within six to twelve months.

    Short term · Reported
  • Risk

    The round remains open and unconfirmed; a failure to close at the reported valuation, or at all, would damage the materials-AI narrative and may chill the wider UK deeptech valuation environment given how closely this round has been covered.

    Immediate · Reported
  • Opportunity

    PFAS-removal materials face a compliance-driven commercial demand curve from EU Water Framework Directive enforcement beginning in 2025–26; CuspAI's Kemira work positions it ahead of several years of regulation-mandated purchasing.

    Medium term · Assessed
First Reported In

Update #9 · Private money rebuilds Britain's seed tier

Silicon Republic· 24 Jun 2026
Read original →
Different Perspectives
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.
CDP Venture Capital
CDP Venture Capital
CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.
EDBI
EDBI
Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.
Forbion
Forbion
Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.
British Business Bank
British Business Bank
The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.
Stryker Corporation
Stryker Corporation
Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.